HRMY - CIK 0001802665
The table below shows Harmony Biosciences Holdings, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $27.76M | $33.99M | $31.14M | $42.56M | $28.85M | $12.53M |
| Capital expenditure | - | $128.00K | $5.00K | - | $45.00K | $4.00K |
| Investing cash flow | -$183.65M | $2.36M | -$6.19M | -$1.79M | -$40.05M | -$100.00M |
| Dividends paid | - | - | - | - | - |
Harmony Biosciences Holdings, Inc. reported operating cash flow of $348.20M for fiscal year 2025. That is up 58.4% from $219.82M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$75.44M (FY 2019) to $348.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$7.22M | -$352.00K | -$3.63M | $3.41M | $1.38M | $12.00K |